Ramsay Stattman Vela & Price Inc. trimmed its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 37,648 shares of the medical instruments supplier's stock after selling 1,279 shares during the period. Becton, Dickinson and Company comprises about 1.6% of Ramsay Stattman Vela & Price Inc.'s portfolio, making the stock its 23rd largest holding. Ramsay Stattman Vela & Price Inc.'s holdings in Becton, Dickinson and Company were worth $8,541,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares during the last quarter. E. Ohman J or Asset Management AB boosted its holdings in Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier's stock worth $39,951,000 after buying an additional 20,859 shares during the last quarter. Arete Wealth Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $767,000. Busey Bank boosted its holdings in shares of Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier's stock worth $15,031,000 after purchasing an additional 2,399 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier's stock worth $720,089,000 after purchasing an additional 1,317,723 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Becton, Dickinson and Company
In other news, EVP Roland Goette sold 4,483 shares of the company's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the sale, the executive vice president now owns 24,345 shares of the company's stock, valued at approximately $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 2,838 shares of the company's stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total value of $633,810.54. Following the sale, the executive vice president now directly owns 6,141 shares in the company, valued at $1,371,469.53. This represents a 31.61 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,544 shares of company stock valued at $2,370,309. 0.36% of the stock is currently owned by company insiders.
Becton, Dickinson and Company Trading Down 0.2 %
Shares of BDX stock traded down $0.39 during trading on Friday, hitting $227.54. 1,920,647 shares of the stock traded hands, compared to its average volume of 2,087,390. The firm has a market capitalization of $65.34 billion, a P/E ratio of 37.80, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The firm's fifty day moving average price is $232.90 and its 200-day moving average price is $233.29.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company announced that its board has authorized a share repurchase program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company's management believes its shares are undervalued.
Becton, Dickinson and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is currently 69.10%.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on BDX. Piper Sandler boosted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a report on Tuesday, January 28th. StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, February 12th. Finally, Barclays boosted their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $278.29.
Read Our Latest Stock Report on BDX
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
